Dupilumab (Dupixent)
Sanofi
Description
Pre-filled syringe and pre-filled pen: 200mg, price on application; 300mg, price on application
Indications
Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. It is also indicated for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.
Contraindications
Hypersensitivity to the active substance or to arginine hydrochloride, histidine, polysorbate 80 (E433), sodium acetate trihydrate, glacial acetic acid (E260), sucrose or water for injections
Sizes Available
Dupilumab is a biologic fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
More on: Systemic eczema treatments